Pharma companies Unichem Laboratories and Lupin are separately recalling certain batches of drugs from the US market due to quality issues.
As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Unichem is voluntarily recalling 1,90,992 bottles of Clonodine Hydrochloride tablets, which are used to treat high blood pressure.
Unichem Pharmaceuticals (USA), the US-based arm of the company, is recalling the drug for "failed impurities/ degradation specifications".
There can be "potential migration of benzophenone at very low level into the product from container", the US health regulator noted in the report.
The specified batch, which is being recalled, has been manufactured at Unichem's Goa-based facility.
ALSO READ: Glenmark Pharma gets USFDA nod for drug to treat multiple sclerosis
The USFDA has classified the action as a Class-III recall, which is initiated in a situation "in which use of or exposure to a violative product is not likely to cause adverse health consequences."
Similarly, the US-based arm of Lupin is voluntarily recalling 4,224 bottles of a product in the country.
The Class-II recall is on account of "Product Mix Up: Lisinopril 10 mg tablets were found in Lisinopril 5 mg 1000-count bottle," the report said.
Lisinopril tablets are used to treat high blood pressure.
The product has been manufactured at Mumbai-based Lupin's Nagpur plant.
As per USFDA, a Class-II recall is initiated in a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)